Abstract
Since the sequencing of the human genome, a key goal has been to make personalised medicine an everyday reality. Research that recognises a correlation between genetic make-up and a future health outcome is not enough. Considerably more research is necessary to understand how genes, drugs and other environmental factors work together, and how they work in particular individuals. Only then will we have enough knowledge for genomic medicine to be useful in a clinical setting. An important and complex policy issue is whether intellectual property policies are working effectively to support the achievement of this bold objective. On 1 May 2015 the University’s Centre for Law, Medicine and Life Sciences (LML) and the Centre for Science and Policy (CSaP), both based at the University of Cambridge, hosted an expert workshop to discuss these issues. This paper reports on the results of the meeting. It covers diverging views on the role of IP for the realisation of genomic medicine, expert reactions to recent US Supreme Court rulings, recent trends in IP strategies, and emerging issues for IP policies and biobanks.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
